MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
0.4333
+0.0147
+3.51%
Pre Market: 0.4301 -0.0032 -0.74% 04:00 06/25 EDT
OPEN
0.4150
PREV CLOSE
0.4186
HIGH
0.4584
LOW
0.4135
VOLUME
150
TURNOVER
0
52 WEEK HIGH
2.300
52 WEEK LOW
0.3820
MARKET CAP
82.01M
P/E (TTM)
-2.4522
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HRTX last week (0615-0619)?
Weekly Report · 3d ago
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
TipRanks · 06/16 19:17
Weekly Report: what happened at HRTX last week (0608-0612)?
Weekly Report · 06/15 09:41
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)
Seeking Alpha · 06/10 13:00
Heron Therapeutics (HRTX) Receives a Buy from H.C. Wainwright
TipRanks · 06/08 10:36
Weekly Report: what happened at HRTX last week (0601-0605)?
Weekly Report · 06/08 09:38
X4, TripAdvisor, Heron, DigitalOcean, Shake Shack Trending
TipRanks · 06/06 09:01
Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday
Benzinga · 06/03 12:52
More
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.

Webull offers Heron Therapeutics Inc stock information, including NASDAQ: HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.